Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors

[1]  Liming Chen,et al.  Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis , 2022, Frontiers in Pharmacology.

[2]  J. Pastor,et al.  Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients , 2022, Veterinary sciences.

[3]  G. Glikin,et al.  Therapeutic potential of the cytosine deaminase::uracil phosphoribosyl transferase/5-fluorocytosine suicide system for canine melanoma. , 2021, Veterinary and comparative oncology.

[4]  P. Erbs,et al.  Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs , 2021, BMC Veterinary Research.

[5]  Bin Zhang,et al.  Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses , 2021, Frontiers in Oncology.

[6]  G. Hutter,et al.  Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs , 2021, Cancers.

[7]  J. Foloppe,et al.  Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs , 2020, Scientific Reports.

[8]  J. Foloppe,et al.  Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer , 2020, Molecular therapy oncolytics.

[9]  J. Foloppe,et al.  Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs , 2020, BMC Veterinary Research.

[10]  P. Buracco,et al.  Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy , 2019, Cancer Immunology, Immunotherapy.

[11]  J. Foloppe,et al.  The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism , 2019, Molecular therapy oncolytics.

[12]  P. Black,et al.  The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer. , 2019, Human gene therapy.

[13]  A. Hemminki,et al.  Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus , 2018, Molecular therapy oncolytics.

[14]  B. Séguin,et al.  Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma , 2018, Viruses.

[15]  O. Matveeva,et al.  Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study) , 2018, Front. Vet. Sci..

[16]  M. Coffey,et al.  Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours , 2018, Veterinary and comparative oncology.

[17]  S. Russell,et al.  Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer , 2017, Molecular Cancer Therapeutics.

[18]  L. Zitvogel,et al.  Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. , 2017, Cancer research.

[19]  G. Daniels,et al.  Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma , 2017, Clinical Cancer Research.

[20]  M. Dey,et al.  Immune System, Friend or Foe of Oncolytic Virotherapy? , 2017, Front. Oncol..

[21]  Edward Jackson,et al.  Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  H. Zeh,et al.  Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  C. London,et al.  Dogs as a Model for Cancer. , 2016, Annual review of animal biosciences.

[24]  S. Kuo,et al.  Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma , 2015, BMC Cancer.

[25]  J. Foloppe,et al.  Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment , 2015, Oncoimmunology.

[26]  D. Thamm,et al.  Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2015, Veterinary and comparative oncology.

[27]  Matthew Breen,et al.  Comparative oncology: what dogs and other species can teach us about humans with cancer , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[28]  G. Linette,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Paradiso,et al.  A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. , 2013, Critical reviews in oncology/hematology.

[30]  M. Bloomston,et al.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.

[31]  A. Dispenzieri,et al.  Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses , 2012, Gene Therapy.

[32]  Aaron Fenster,et al.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans , 2011, Nature.

[33]  E. G. Domínguez,et al.  Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Banerjee,et al.  Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[35]  J. Diallo,et al.  Intelligent Design: Combination Therapy With Oncolytic Viruses. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  D. Sze,et al.  Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. , 2008, The Lancet. Oncology.

[37]  J. Foloppe,et al.  Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus , 2008, Gene Therapy.

[38]  Bo Wu,et al.  [Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating]. , 2006, Ai zheng = Aizheng = Chinese journal of cancer.

[39]  P. McCue,et al.  Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. , 2001, The Journal of urology.

[40]  M. Onda,et al.  Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  H. Makuuchi,et al.  A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients , 2001, Cancer Chemotherapy and Pharmacology.

[42]  H. Guchelaar,et al.  Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. , 2000, The Journal of antimicrobial chemotherapy.

[43]  P. Leroy,et al.  In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. , 2000, Cancer research.

[44]  H. Guchelaar,et al.  Flucytosine: Correlation between Toxicity and Pharmacokinetic Parameters , 2000, Chemotherapy.

[45]  E. Macewen,et al.  Spontaneously Occurring Tumors of Companion Animals as Models for Human Cancer , 2000, Cancer investigation.

[46]  H. Roenigk,et al.  Immunotherapy of malignant melanoma with vaccinia virus. , 1974, Archives of dermatology.

[47]  G. Westbury,et al.  Use of Vaccinia Virus in the Treatment of Metastatic Malignant Melanoma , 1970, British medical journal.

[48]  J. Limacher,et al.  Vectorized Gene Therapy of Liver Tumors: Proof of Concept of TG4023 (MVA-FCU1) in Combination with Flucytosine. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. , 2016, Veterinary and comparative oncology.

[50]  H. M. Pinedo,et al.  Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma , 2004, Cancer Chemotherapy and Pharmacology.

[51]  B. Reigner,et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.

[52]  W. Adams,et al.  Naturally occurring tumors in dogs as comparative models for cancer therapy research. , 1994, In vivo.